Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
1.180
-0.070 (-5.60%)
At close: Dec 5, 2025, 4:00 PM EST
1.240
+0.060 (5.08%)
After-hours: Dec 5, 2025, 6:55 PM EST
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -67.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Citius Pharmaceuticals stock has a target of 6.00, which predicts a 408.47% increase from the current stock price of 1.18.
Price Target: $6.00 (+408.47%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Citius Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +408.47% | Dec 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +408.47% | Aug 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +408.47% | Jun 30, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +408.47% | Jun 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +662.71% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
65.10M
EPS This Year
-3.30
from -5.97
EPS Next Year
0.37
from -3.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 82.2M | ||||
| Avg | n/a | 65.1M | ||||
| Low | n/a | 48.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.52 | 2.00 | ||||
| Avg | -3.30 | 0.37 | ||||
| Low | -3.96 | -0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.